||Nicotinamide N-oxide is recognized as an in vivo metabolite of nicotinamide which is a precurser of nicotinamide-adenine dinucleotide (NAD+) in animals. The enzyme that catalyzes t
||10058-F4 is a cell-permeable thiazolidinone that specifically inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression; induces cell-cycle ar
||10074-G5 is an inhibitor of c-Myc-Max dimerization.
||Mycro 3 is potent and selective for c-Myc in whole cell assays.
||ML327 is a blocker of MYC which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).
||Sanggenol L shows higher cytotoxicity against human oral tumor cell lines (HSC-2 and HSG) than against normal human gingival fibroblasts (HGF), it induces apoptosis via caspase act
||Diphyllin could be characterized as a new V-ATPase inhibitor in treating gastric cancer and inhibiting the phosphorylation of LRP6 in Wnt/β-catenin signaling.
||Aaptamine functions as a proteasome inhibitor, it activates p21 promoter in a p53-independent manner.
||MYCi975 is an orally active inhibitor of MYC.
||APTO-253 inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity
||CBP/EP300-IN-2 is an inhibitor of CBP/EP300 (IC50s: 1.07 nM and 5.96 nM for CBP/HTRF and Myc) extracted from patent WO2017205538A1 (example 25).
||KJ Pyr 9
||KJ Pyr 9 is an MYC inhibitor (Kd: 6.5 nM in vitro assay).
||KSI-3716 is an inhibitor of c-Myc.
||sAJM589 is a Myc inhibitor(IC50: 1.8 μM).
||MYCi361 is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM).
||Vicenin -2 has hepatoprotective, anti-cancer, antioxidant and anti-inflammatory activities, and DTL co-administration is more effective than either of the single agents in androgen
||Coronarin D shows promising antifungal activity against C. albicans in vitro, the minimum inhibitory concentration (MIC) and the minimum fungicidal concentration (MFC) were 2 and 4
||Moracin C and moracin D, new phytoalexins from diseased mulberry, are antifungal compounds. Moracin may be protective influence in tumor promotion, utilization of Moracin may open
||Moracin treatment can inhibit the double 12-O-tetradecanoylphorbol 13-acetate (TPA) treatment-induced morphological changes reflecting inflammatory response, including leucocyte in